Nasdaq

TransCode Therapeutics and BRAIN Biotech join forces to develop a CRISPR-derived technology platform for cancer treatment

BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced ...
Nasdaq

TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138

BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced ...
Seeking Alpha

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced a ...

TransCode Therapeutics to Host R&D Webcast on June 18, 2026

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage oncology company advancing a three-platform pipeline in RNA therapeutics and immuno-oncology, today announced it will host its first live ...
Business Insider

TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138

BOSTON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced ...
MarketWatch

TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028

The MarketWatch News Department was not involved in the creation of this content. BOSTON, April 7, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ, the "Company"), a clinical stage ...
Benzinga.com

Why TransCode Therapeutics (RNAZ) Stock Is Diving

TransCode Therapeutics shares are trading lower by 16% during Monday's session. The company announced a 1-for-33 reverse stock split. Unlock your all-in-one trading dashboard with real-time alerts, ...
Seeking Alpha

TransCode Therapeutics Reports Second Quarter 2023 Results; Provides Business Update

BOSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial ...
Morningstar

TransCode Therapeutics Inc RNAZ

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) a clinical stage company pioneering immuno-oncology and RNA for the treatment of ...
Benzinga.com

Why TransCode Therapeutics (RNAZ) Stock Is Getting Hammered

TransCode Therapeutics shares are trading lower by 40.6% during Monday's session. The company disclosed plans for a potential reverse stock split in an open letter to its shareholders. Up Next: Get 5 ...